Caroline Sanchez, MD
Colon & Rectal Surgery · Fairfax, VANPI 1558536789
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Intuitive Surgical at 55.5% of the total. That places this record below the midpoint for colon & rectal surgery clinicians in VA, where the typical reported total is $1,889.
Across 7 payments — averaging $35.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$137
- Stryker$25
- AbbVie$24
- Takeda Pharmaceuticals U.S.A., Inc.$23
- Covidien LP$20
- Shire North American Group Inc$18
What the payments were for
- Food & beverage$247100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $137 |
| Stryker | 1 | $25 |
| AbbVie | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Covidien LP | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
How this compares
$247 in reported general payments places this provider in the 15th percentile of 46 colon & rectal surgery providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 14 | $73 |
| Metronidazole | 11 | $12 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Fairfax
- Kimberly MatzieFairfax$28K
- Othon WiltzFairfax$4K
- Paul SavocaFairfax$3K
- Rebekah KimFairfax$2K
- Katherine KhalifehFairfax$2K
- Christina ChengFairfax$2K
- John TillouFairfax$1K
- Daniel OtchyFairfax$289
- Anna KataFairfax$171
- Andrew VorenbergRichmond$560K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.